Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 23

Trial Status

Completed4

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT00005840Phase 1Completed
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Endometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaStage III Uterine Corpus Cancer+1 more
Principalinvestigator
NCT00025220Phase 2Completed
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Recurrent Uterine Corpus SarcomaUterine Corpus Leiomyosarcoma
Principalinvestigator
NCT00025506Phase 2Completed
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
Principalinvestigator
NCT00217633Phase 2Completed
Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell Carcinoma+2 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Matthew S. Block, M.D., Ph.D.

Mayo Clinic in Rochester

Related
2 trials

Shared therapeutic areas:

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma+2 more
Similarity Score13%

Peter Rose

Gynecologic Oncology Group

Related
2 trials

Shared therapeutic areas:

Cervical AdenocarcinomaCervical Squamous Cell CarcinomaCervical Adenosquamous Carcinoma+1 more

Worked with same sponsors:

Gynecologic Oncology GroupNational Cancer Institute (NCI)
Similarity Score10%

Sharon Manne

Rutgers Cancer Institute of New Jersey

Related
5 trials

Shared therapeutic areas:

Stage III Uterine Corpus CancerStage IV Uterine Corpus CancerUterine Carcinosarcoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

John K Chan

NRG Oncology

Related
3 trials

Shared therapeutic areas:

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaRecurrent Cervical Carcinoma

Worked with same sponsors:

Gynecologic Oncology GroupNational Cancer Institute (NCI)
Similarity Score8%

Jyoti S Mayadev

NRG Oncology

Related
3 trials

Shared therapeutic areas:

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Jermaine Coward

Integrated Haematology and Oncology Network

Related
2 trials

Shared therapeutic areas:

Endometrial Clear Cell AdenocarcinomaEndometrial Serous Adenocarcinoma
Similarity Score5%

Jorge Oldan, MD

University of North Carolina, Chapel Hill

Related
4 trials

Shared therapeutic areas:

Cervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma
Similarity Score5%

Robert Coleman

M.D. Anderson Cancer Center

Related
2 trials

Shared therapeutic areas:

Endometrial Clear Cell AdenocarcinomaEndometrial Serous Adenocarcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score5%

Lei Li, M.D.

Peking Union Medical College Hospital

Related
46 trials

Shared therapeutic areas:

Recurrent Cervical CarcinomaCervical Adenocarcinoma
Similarity Score5%

Mihitha Ariyapperuma

One Clinical Research (OCR)

Related
1 trials

Shared therapeutic areas:

Endometrial Clear Cell AdenocarcinomaEndometrial Serous Adenocarcinoma
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT00005840Phase 1PrincipalInvestigator

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Endometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaStage III Uterine Corpus Cancer+1 more
Completed
NCT00025220Phase 2PrincipalInvestigator

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Recurrent Uterine Corpus SarcomaUterine Corpus Leiomyosarcoma
Completed
NCT00025506Phase 2PrincipalInvestigator

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
Completed
NCT00217633Phase 2PrincipalInvestigator

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell Carcinoma+2 more
Completed

All 4 trials loaded